


Fact Sheet *Targeting, Attacking & Eradicating Cancer*

JENNEREX, INC. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for cancer. Jennerex's lead product candidate, JX-594, which can be delivered both intratumorally and intravenously, and is currently in an international, randomized, Phase 2b clinical trial (TRAVERSE) in patients with advanced primary liver cancer who have failed sorafenib therapy. Preliminary clinical data have shown selective tumor cell killing as well as a good tolerability profile. The company is planning for late-stage clinical trials and continues to evaluate JX-594's promising applicability to multiple tumor types. Clinical trials of JX-594 in colorectal cancer are also under way. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the reduction of the blood supply to tumors through vascular targeting and destruction and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy.

Four trials completed. Three ongoing. Over 150 patients treated to date.

Products	Preclinical	Phase 1	Phase 2	Phase 3
JX-594				
Liver				
Colorectal				
JX-929				
Pancreatic				
Breast				
JX-Next Generation				
Various				



RECENT MILESTONES

- ▶ Appointed Laurent Fischer, MD, to the position of president and CEO.
- ▶ Published clinical proof-of-concept of JX-594 in journal, *Nature*.
- ▶ Demonstrated survival benefit in Phase 2 JX-594 trial in liver cancer. Phase 2b trial under way.
- ▶ Presented Phase 1 clinical data showing safe and effective intravenous delivery of JX-594.
- ▶ Entered an exclusive partnership for the development and commercialization of JX-594 in Europe.

JENNEREX AT A GLANCE

- ▶ Private, clinical-stage biotech company
- ▶ Three clinical-stage product candidates for cancer
- ▶ Headquartered in San Francisco, CA
- ▶ R&D operations in Canada & South Korea
- ▶ Over \$55mm raised to date through private financings
- ▶ Strategic regional partnerships
- ▶ Approx. 45 employees


CONTACT US

Jennifer Cook Williams
Investor Relations
Office: 360-668-3701
Jennifer@cwcomm.org

Jennerex, Inc.
450 Sansome Street, 16th Floor,
San Francisco, CA, 94111
www.jennerex.com

Our first-in-class products wage a multipronged attack on cancer.


Jennerex's products are designed using proprietary SOLVE™ (Selective Oncolytic Vaccinia Engineering) platform. SOLVE takes advantage of the natural attributes of poxviruses as well as their ability to be genetically engineered to produce safe, therapeutic viruses that can infect solid tumors both systemically and locally. SOLVE platform has the ability to produce novel, multi-functional products, such as JX-594, that can selectively express high concentrations of complementary therapeutics. We plan to continue employing SOLVE to create new therapeutics that broadly target different types of cancers in our early-stage pipeline.



David H. Kirn and Steve H. Thorne (2009). Nature Reviews Cancer. Vol 9, 65.

JX-594 – ERADICATES CANCERS REFRACTORY TO STANDARD THERAPIES

- ▶ Cancer biotherapeutic derived from a proprietary breakthrough class of targeted and armed oncolytic vaccinia viruses.
- ▶ Currently in Phase 2 trials. Late-stage trials being planned.
- ▶ Interim Phase 2 data demonstrated increased survival in high-dose group vs. low dose group in advanced liver cancer.
- ▶ Excellent safety profile (transient flu-like symptoms) when compared with standard of care.
- ▶ Both intratumoral and intravenous delivery have resulted in anti-cancer effects across multiple cancer types.
- ▶ JX-594 is genetically modified by deleting its thymidine kinase gene to enhance cancer selectivity and is armed with GM-CSF gene to stimulate systemic anti-tumoral tumoral immune response.



Jennerex virus JX-594 eradicates a liver cancer tumor metastasis in neck (as shown via photos and corresponding PET scan images).

MANAGEMENT TEAM & BOARD

Executive Management Team

Laurent Fischer, M.D. - President & Chief Executive Officer
 John Bell, Ph.D. - Chief Scientific Officer & Director
 David H. Kirn, M.D. - President, Research and Development; Founder; and Chief Medical Officer
 Lara Longpre, M.Sc., M.B.A. - Chief Operating Officer
 Greg Schafer, M.B.A. - Chief Financial Officer

Ursula Fritsch, PharmD. - VP, Regulatory Affairs
 Tae-Ho Hwang, DDS, Ph.D. - Research Advisor & Head of Pusan Research Site
 James Burke, M.D. - VP, Clinical Research
 Lucy Chang, Ph.D. - VP, Quality and Analytical Development
 Christopher Peetz - VP, Corporate Development

Board of Directors

Brennan R. Mulcahy, LL.D., Chairman of Jennerex & CEO of American Solar Direct
 John Bell, Ph.D., Chief Scientific Officer of Jennerex
 Peter D. Charbonneau, M.B.A., Gen. Partner, Skypoint Capital Corp.
 Laurent Fischer, M.D., President & Chief Executive Officer, Jennerex
 Mitchell H. Gold, M.D., Executive Chairman of the Board of Dendreon Corporation
 Terry Hermiston, Ph.D., VP, Biologics Research, Bayer HealthCare

David Kirn, M.D., President, Research and Development; Founder; and Chief Medical Officer, Jennerex
 Ken Newport, C.A., M.Acc.
 Hartley S. Stern, M.D., FRCS(C) FACS, Exec. Dir., Jewish General Hospital & Professor of Surgery, McGill University
Special Advisor to the Board: Hoyoung Huh, M.D., Ph.D., Chairman of Geron & BiPar Sciences

COMMITTED TO REACHING PATIENTS GLOBALLY THROUGH KEY PARTNERSHIPS

- Transgene:** Exclusive license to develop and commercialize JX-594 in Europe and neighboring countries.
- Green Cross Corporation:** Exclusive license to develop and commercialize JX-594 in South Korea.
- Lee's Pharmaceutical Ltd.:** Exclusive license to develop and commercialize JX-594 in China.